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ABSTRACT
Detection o f Glial Interlcukin-6 Release: Development 
o f a Novel Interleuldn-6 ELISA
by
Kay-Lynn Bowman
Dr. Bryan L. Spangelo, Examination Committee Chair 
Associate Professor and Chair o f  the Department o f  Chemistry 
University o f  Nevada, Las Vegas
The development o f an interleukin-6 (IL-6) enzyme-linked immunosorbent (ELISA) 
assay resulted in a detection range o f 1 ng/ml to 10 ng/mL IL-6. The limit o f  detection 
(LOD) for IL-6 was 0.25 ng/mL. Troubleshooting techniques were attempted including 
matrix effects, non-specific binding, and coating buffer pH differences. In comparison to 
the ELISA, the LOD for IL-6 using the 7TDI bioassay was 2-5 pg/mL. Therefore the 
7TDI bioassay was implemented for the experiments described in this study. IL-6 is a 
cytokine known to stimulate B-cell differentiation and to activate T-cells. IL-6 is 
elevated in inflammatory and neurodegenerative diseases. Interleukin-Ip (IL-IP) 
stimulates IL-6 release from glial cells. Catecholamines and IL-ip synergistically release 
IL-6 from glial cells. In the rat C6 glioma cell line, the role o f indoleamines was 
examined alone and in combination with IL-ip resulting in no synergistic effects on IL-6 
release. Isoproterenol synergistically acted with IL -ip  on stimulating IL-6 release. IL-I 
receptor antagonist decreased the IL-ip stimulation o f  IL-6. These results demonstrate 
that the catecholamines and IL-ip play a role in the regulation o f  IL-6 expression.
iii
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CHAPTER 1 
INTRODUCTION
Background and Project Description 
This study includes the development of an ELISA and the continuing investigations 
o f  IL-6 release from C6 glioma cells. The attempt at developing a novel ELISA for the 
detection o f  IL-6 requires the understanding o f the types o f immunoassays available and 
how they can be applied to a 96-well assay format. This will be discussed later in this 
introductory section.
Cross-communication between the nervous/endocrine/immune systems is an 
important area for understanding how each system contributes to homeostasis and 
therefore will be discussed in general terms, lnterluekin-6, a cytokine released from glial 
cells, plays a role in neurodegeneration. The regulation o f  lL-6 release is important for 
finding potential therapeutic interventions.
Specifically 1 intend the following;
1. To describe the development of the IL-6 ELISA including standard curve 
data and trouble shooting techniques.
2. To determine what mechanisms control the release o f lL-6 from C6 cells 
including the effects o f IL-lp, IL-lra, serotonin and melatonin.
3. To interpret data on the mechanisms o f IL-6 release to the potential effects 
lL-6 has on neurodegeneration and inflammation.
1
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Several aspects o f human biochemistry are significant to the above stated goals. The 
immune system, the neuroendocrine system, cytokines, and neurotransmitters are all 
important topics that must be discussed to fully understand their relationship in 
explaining what effects lL -6  has on neurodegeneration and in flam m ation
Immune System
The immune system is composed of two main components; the humoral immimg 
response and the cell-mediated immune response. The humoral response allows for the 
immune system to remember an infectious agent and prevent it fi’om causing disease at a 
later time. Cells o f  the humoral response consist o f T  and B lymphocytes (T and B cells). 
B cells have the ability to release antibody that binds to its target antigen. The T cells 
control B cell development and antibody production. The T cells release soluble factors 
(cytokines) which activate phagocytes to destroy pathogenic material they engulf through 
endocytosis (Roitt et al., 1993).
The cell-mediated immune response, acting as a first line o f  defense against 
infection, mainly consists o f  leukocytes (e.g., monocytes, macrophages, and 
polymorphonuclear neutrophils (PMNs)). Phagocytes are derived fi*om bone marrow 
stem cells and function to engulf and destroy foreign particles that they encounter for 
presentation as antigens to T cells. Phagocytes are present in the brain as microglial 
cells, in the liver as Kupffer cells, in the blood as monocytes, and as macrophages in the 
lung, spleen, and lymph tissues (Roitt et al., 1993).
The thymus, a primary lymphatic tissue, is responsible for the development o f 
prothymocytes into mature T lymphocytes. Cells o f the thymus release thymic peptides
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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and hormones such as thymosin a% (TaO, thymuiin and MB35 (Spangelo et al., 1997). A 
thymic preparation o f  the bovine thymus consisting o f  low molecular weight peptides, 
termed thymosin fraction 5 (TF5), has T lymphocyte-regulating properties (Spangelo,
1995). The thymic peptides and cytokines can influence T cell differentiation, and thus 
the immune response. B cells develop in the bone marrow o f adult m am m als. Antigenic 
stimulation results in the proliferation o f B cells and the differentiation o f these cells into 
plasma cells or memory cells. Both T and B cells are important for aiding the immune 
system to recognize pathogens. Their functions are coordinated to fight against infection. 
The T cells accomplish this coordination by releasing cytokines (e.g., interferon, 
interleukins, colony stimulating factors, and tumor necrosis factors) that signal B cells to 
divide and differentiate into antibody secreting plasma cells. Antibody proteins have 
specific binding regions; the Fab (fragment antigen binding) region for binding antigen 
and the Fc (fragment crystallizable) that binds to phagocytes. It is the recognition o f the 
antigen and the production of antibodies against the antigen that allows for an immune 
response.
Neuroendocrine System 
The neuroendocrine system is composed o f  specialized neuroendocrine cells found 
in the hypothalamic region of the brain. This region regulates the secretion o f  hormones 
from the pituitary gland (Cooper et al., 1996). The pituitary gland is composed o f  both 
glandular and neural tissue, thus allowing for a brain-pituitary axis. This axis is most 
recognized in the hypothalamus-pituitary-adrenal (HPA) axis (Hadley, 1992). The 
pituitary neural tissue forms the neurohypophysis and consists o f the median eminence.
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the infundibular stem, and the neural lobe (McCann et al., 1996). The pituitary receives 
its blood supply from hypophysial arteries that penetrate the hypophysial stalk as well as 
the hypothalamus. The anterior pituitary lobe is vascularized by hypophysial portal 
vessels that arise from the capillary beds within the median eminence o f the 
hypothalamus (i.e., the primary capillary plexus). The portal blood system originating in 
the median eminence o f  the hypothalamus sends vessels derived from this plexus down 
the stalk to the anterior lobe to form the secondary capillary plexus. This vasculature 
provides an important link for carrying hormonal information from the hypothalamus to 
the pituitary (Figure 1) (Hadley, 1992). This link allows for hypothalamic 
neuroendocrine control o f  adrenocorticotropic hormone (ACTH), growth hormone (GH), 
thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH), and luteinizing 
hormone (LH) secretion from the anterior pituitary (McCann et al., 1996). The central 
nervous system (CNS) relays electrochemical signals through neuronal routes to release 
neurotransmitters that affect synaptic transmission. These neurohormones include 
monoamine neurotransmitters released from serotonergic, dopaminergic and 
noradrenergic neuronal pathways. Axons from these neurons extend into the 
hypothalamus to affect select nuclei. For example, noradrenergic pathways stimulate the 
corticotropin releasing hormone (CRH) neurons in the paraventricular nucleus resulting 
in enhanced CRH secretion and subsequently ACTH secretion from the anterior pituitary.
Interleukin Cytokines 
Cytokines, mediators o f the immune response, have the ability to affect 
neuroendocrine function and hormone secretion. The cytokine family o f peptides
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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consists o f interleukins (1 to 18), tumor necrosis factor-a (TNF-a) and—P, colony- 
stimulating factor (CSF), interferons, transforming growth factors-P, chemokines, and 
growth factors (Casey, 1996). Cytokines can participate in a variety o f functions 
including inflammation, to serve as growth or regulatory fectors, and to facilitate the 
maintenance o f normal immune function. Interleukin-ip (IL-ip), TNF-a and sometimes 
interleukin-6 (IL-6) are considered as inflammatory cytokines responsible for the acute- 
phase response to infection (Arvin et al., 1996).
Interleukin-1 production by lymphocytes and monocytes affects inflam m ato ry  and 
cell-mediated immune responses by activation o f lymphocytes, macrophage stimulation, 
increased endothelial adhesion, fever induction, and stimulation o f acute phase proteins 
(Roitt et al., 1993). The lL-1 gene family consists o f IL-la, IL -ip and the IL-1 receptor 
antagonist (IL-lra). IL -la  and IL-ip are 22% homologous in terms o f their primary, 
mature amino acid sequence. Both are synthesized as 31-kDa precursors (271 and 269 
amino acids respectively) and are processed to 17.5-kDa molecular weight polypeptides 
(159 and 153 amino acids respectively) (Spangelo, 1999). Precursor IL -la  (ProIL-la) 
is not normally secreted and remains predominantly intracellular. ProIL-lp is cleaved at 
the cell surface by the IL-ip converting enzyme (ICE), and allows for the secretion of the 
biologically active, mature form o f IL-ip. IL-lra stqxpresses the biological activity of IL- 
l a  and IL -ip by binding to an lL-1 receptor and not inducing an intracellular signaling 
response. IL-lra is synthesized with a signal peptide and can be readily transported out 
of cells (Dinarello, 1997). The primary amino acid sequence homology for IL-lra and 
£L-ip is 26%, which is greater than that between IL -la  and IL-ip.
There are two types o f receptors for IL-1 binding. Type I and Type H. IL-lp has two
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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binding sites on the IL-1 Type 1 receptor allowing for intracellular signaling to occur. EL- 
1P can also bind lL-1 Type II receptors, but binding does not transduce an intracellular 
signal. Therefore, the IL-1 Type H receptor is a  decoy receptor for IL -ip  binding. The 
lL-1 Type 1 receptor forms a complex with lL-1 receptor accessory proteins including IL- 
1 receptor-associated serine/threonine kinase (IRAK). IRAK becomes phosphorylated 
and interacts with tumor necrosis factor receptor-associated protein (TRAF6), which has 
been implicated in the activation o f NFkB (Kanakaraj et al., 1998). When IL-ip binds to 
the Type 1 receptor cellular signaling begins (Spangelo, 1999; Dinarello, 1997). Signal 
transduction for IL-ip is not fully understood. IL -ip has been shown to breakdown 
phospholipids and increase arachidonic acid release via phospholipase Az activation 
(O’Neill et al., 1995). IL-ip also increased lL-6 release and induced the hydrolysis o f 
phosphatidylcholine by phospholipase Az in rat anterior pituitary cells in vitro (Spangelo 
et al., 1991). Zumwalt and colleagues (1999) reported that IL -ip enhanced the release o f 
EL-6 from rat C6 glioma cells. These investigators implicated lysophosphatidylcholine as 
a second messenger leading to IL-6 release. Second messenger cascade signaling results 
in the activation of mitogen-activated protein (MAP) kinases and tyrosine kinases that 
lead to the activation of transciption factors NFkB , jun-fos dimer A PI, and NF-1L6 
(O’Neill, 1995; Bankers-Fulbright et al., 1996; Zumwalt et al., 1999).
lnterleukin-6 can function as a chemokine and an inflammatory cytokine.
IL-6 has a variety o f physiological and biological functions (Van Snick, 1990) including 
B cell differentiation, T cell activation and proliferation, and induction o f the acute phase 
response. Human DL-6 is a glycoprotein that has a molecular mass ranging from 
21 -28 kDa depending on cellular source and preparation. The rat IL-6 amino acid
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
sequence derived from peritoneal exudate cells (Northemann et al., 1989) is 93% 
identical to murine lL-6 but only 58% identical to human IL-6. Unlike human lL-6 that 
contains N- and 0-glycosylation, rat IL-6 lacks N-glycosylation sites.
lL-6 binds to a trimeric receptor consisting o f  a glycoprotein a-subunit (gp80) and a 
homodimer o f gpl30. It is the homodimerization o f the gpl30 unit upon lL-6 binding 
that completes the trimeric receptor and triggers the Jak-Stat signaling cascade pathway 
(Spangelo, 1999). Other cytokines and growth hormones also utilize this pathway. Jak 
(Janus kinase) tyrosine kinases activated by crossphosphorylation subsequently 
phosphorylate the receptor itself as well as the Stat (signal transducers and activators o f 
transcription) proteins. The activated Stat proteins then homo- or heterodimerize and 
translocate to the nucleus for transcriptional activation. In the case o f IL-6 binding, the 
a-chain o f  the receptor results in the dimerization o f gpl30 that in turn activates Jakl and 
Jak2 tyrosine kinases to induce activation o f  Statl and Stat3 proteins. The Statl and 
StatS proteins enter the nucleus o f  the cell as homo- or heterodimers, bind to DNA for the 
synthesis o f mRNA and finally nascent protein (Spangelo, 1999). The IL-6 soluble 
receptor (IL-6sr) is the soluble form o f  the IL-6 receptor a-chain. IL-6 forms a complex 
with the IL-6sr, which binds and signals through gpl30 inducing a response (Van 
Wagoner et al., 1999).
IL -lp and TNF-a (Benveniste et al., 1990; Sparacio et al., 1992) induce lL-6 release 
from astrocytes. The 5’ promoter region o f the EL-6 gene has three fimctional cis- 
regulatory elements: the cyclic AMP-responsive, glucocorticoid responsive and multi­
response elements. The multi-response element is activated by IL-1, TNF-a, senun, 
phorbol esters (PMA) and IL-6 (Jones, 1994). Glial cells in the CNS are continually
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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exposed to diverse neurotransmitters and neuropeptides. Norepinephrine (NE) and 
isoproterenol (IPX; a P-adrenergic agonist) (Maimone et al., 1993; Zumwalt et al., 1998) 
induce the release oflL-6 from astrocytes, and in the presence o f  IL-1 P these agents have 
a synergistic effect on lL-6 release. TNF-a and IL-ip in the presence o f lL-6sr also have 
a synergistic effect on the production o f lL-6 from astrocytes (Van Wagoner et al., 1999). 
Vasoactive intestinal peptide (VIP), a neuropeptide, also induces EL-6 secretion from 
astrocytes (Maimone et al., 1993).
lL-6 has been implicated in a multitude o f neurodegenerative and inflammatory 
diseases such as Alzheimer’s disease (AD)(Kalman et al., 1997) and rheumatoid arthritis 
(Graeve et al., 1993). lL-6 is present in elevated concentrations in AD plaques, linking 
this cytokine to pathological changes in AD (Hull et al., 1996).
Neurotransmitters: Monoamines 
Neurotransmitters are compounds that are synthesized and released pre-synaptically 
(Cooper et al., 1996). Specialized neurons are stimulated by an electrochemical signal 
that results in the release o f  chemical compounds from their storage sites within the cell 
body into the synapse. The effects on the postsynaptic neuron can either be stimulatory 
or inhibitory depending on the receptor present for the particular neurotransmitter. 
Neurotransmitters can also have an effect on the surrounding glial cells.
Dopamine (DA), norepinephrine (NE) and epinephrine (E) belong to the 
catecholamine neurotransmitter family (Figure 2) (reviewed in Cooper et al., 1996).
These neurotransmitters are released from catecholaminergic neurons. In the CNS, 
dopamine represents about 50% o f  the total catecholamines. Dopamine is found in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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discrete regions o f the brain including the nucleus accumbens, the neostriatum and the 
tuberculum olfactorium. Norepinephrine distribution differs from that o f  dopamine in 
that it is more localized in the hypothalamus and generally found in gray matter more that 
white matter. Epinephrine concentrations are low, 5%-17% of NE content (Cooper et al.,
1996).
Catecholamines are formed in sympathetic nerves and ganglia from the amino acid 
precursor tyrosine. The catecholamines are stored in granules within the nerve cell body 
and upon stimulation the contents o f  the granules are released by exocytosis. Once 
released, the catecholamines recognize and bind to specific receptors on the plasma 
membrane o f the adjacent neural cells. Depending on the receptor type, a  signal 
transduction occurs resulting in a cascade o f membrane and intracellular events. The 
three classes o f receptors are a l ,  cc2 and P-adrenergic (P l, p2 subtypes). The adrenergic 
receptor signals by coupling with G proteins (guanine nucleotide-binding regulatory 
proteins). When the neurotransmitter binds to the select receptor, the receptor associates 
with a G-protein to either stimulate or inhibit adenylyl cyclase activity by increasing or 
decreasing the production o f cyclic adenosine monophosphate (cAMP). The P- 
adrenergic receptors couple with the Gs protein thereby stimulating the adenylyl cyclase 
cascade. The az-adrenergic receptors couple with G, protein and inhibits adenylyl 
cyclase activity while ai-adrenergic receptor stimulates the phospholipase C activity 
through a G protein still to be defined (Cooper et al., 1996). Figure 3 shows the proposed 
mechanism for the activation o f adenylyl cyclase.
The catecholamines are just one type of monoamine neurotransmitters. Another type 
of monoamine neurotransmitters is the indoleamines (Cooper et al., 1996). Serotonin (5-
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hydroxytryptamine, 5-HT) is synthesized using the precursor amino acid tryptophan 
(Figure 4). Serotonin is produced in other cells o f  the body but is not able to cross the 
blood-brain barrier. Therefore, the synthesis o f brain serotonin is dependent upon the 
availability o f  tryptophan. Tryptophan is taken in from the diet. Therefore dietary 
protein content can influence brain tryptophan and serotonin levels. Metabolic products 
of serotonin include 5-hydroxy indole acetic acid (5-HIAA) and N-acetyl serotonin. The 
N-acetyl serotonin is converted to melatonin by the pineal enzyme 5-hydroxy indole O- 
methyl transferase. The pineal body is a gland (1 mg in the rat) in the dorsal surface o f 
the hypothalamus. This gland contains all the enzymes required for the synthesis and 
processing o f serotonin which is found in 50 times greater concentration (per gram) in the 
pineal gland than in any other location. Serotonin is catabolized to melatonin in the 
pineal gland. Environmental light and dark patterns affect the circadian rhythm o f both 
melatonin and serotonin. Within minutes o f  the dark cycle, the pineal gland p-adrenergic 
receptors produce an increase in cAMP leading to activation of the N-acetyl transferase 
resulting in synthesis o f  melatonin (Cooper et al., 1996).
In the brain, serotonin-releasing neurons are found in the pons region, and the iq>per 
brain stem. Serotonin neurons innervate the telencephalon and diencephalon by 
projecting their axons along neural tracts to these regions. When stimulated, the neuronal 
tracts release serotonin resulting mainly in inhibitory effects. There are multiple serotonin 
receptors in the CNS including 5-HTia, ib .  i d ,  5-HT2a.2b.2d, S-HTs, 5 -HT4, 5-HT6, and 5- 
HT7. The 5 -HT3 receptors are ion-channel ligand-gated and are found only on neurons; 
the rest o f the receptors are coupled to G-proteins (Table 1). When serotonin binds to the 
selective receptor the following signal transductions may occur: 5-HT| receptor frunily
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has an inhibitory effect on adenylyl cyclase activity while 5 -HT4 s, g 7 receptors have a 
stimulatory effect resulting in an increase in cAMP production (Cooper et al., 1996). 
5 -HT2 receptor family is coupled to a G-protein that signals through phospholipase C 
(PLC) leading to the production o f inositol triphosphate (IP3) and diacyl glycerol (DAG).
Role o f  Cytokines in Inflammation and Neurodegeneration 
Glial cells (neuroglia) consist o f macroglia (astrocytes and oligodendrocytes) and 
microglia (macrophages). Astrocytes, the major glial cells in the CNS, are found in 
regions o f axons, dendrites and in close contact with the surface o f neural blood vessels 
(Cooper et al., 1996). Oligodendrocytes compose the myelin sheath that surroimds 
axons. C6 cells, isolated from a chemically (N-nitrosomethylurea) induced rat brain 
tiunor, are astrocyte-like cells that contain the protein S-100 (acidic protein soluble in 100 
percent saturated ammonium sulfate at neutral pH; Benda, et al., 1968). C6 glioma cells 
also have similar characteristics to the folliculostellate cells of the anterior pituitary in 
that both cell types are known to release IL-6 and contain the S-100 protein (Spangelo et 
al., 1994; Tijerina et al., 1998). Another deflning component found in glial cells is the 
glial fibrillary acidic protein (GFAP) which is often used as a marker for cell 
homogeneity. Ilyin and colleagues (1999) demonstrated that when C6 cells are 
introduced into the third ventricle o f  the rat brain a tumor is formed o f  astrocytic origin 
(positive for GFAP and S-100 protein). The brain tumor formation results in increased 
levels o f  mRNA for IL-1 (3, IL-lra, IL-1 receptor Type I, and TNF-a in the cerebellum, 
hippocampus, and hypothalamus.
Inflammation is a mechanism used to localize and concentrate an infection.
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Inflammation is a mechanism used to localize and concentrate an infection.
Increased blood flow to the infected area, capillary permeability to immune  cells, and the 
migration o f leukocytes to the area o f the infection are all key events leading to 
inflammation. Brain trauma can also elicit an inflammatory response. Brain trauma can 
result from deprivation of oxygen and nutrients, neurotoxic injury, viral infection or 
immunological challenge. Brain inflammation results in gliosis characterized by the 
activation, proliferation and hypertrophy o f  mononuclear phagocytes (e.g., macrophages, 
microglia) (Arvin et al., 1996). Specific cytokines (i.e., interleukin-ip, tumor necrosis 
factor-a and interferon y) can exacerbate the brain damage. Cytokines activate glial cells 
that in turn produce cytokines in response to the stimulation. The blood-brain barrier, 
normally impermeable to immune cells o f  the periphery, becomes leaky due to injury 
allowing for peripheral T lymphocytes, natural killer cells and PMNs to contribute to 
central inflammation. Brain inflammation can result in neuronal loss, edema formation 
and the presence of peripherally derived immune cells (Feuerstein et al., 1998).
Activated astrocytes and microglia may play a role in Alzheimer’s Disease (AD) 
(reviewed in Mrak et al., 1995). Microglia are active in phagocytosis o f  necrotic 
material, and may be responsible for an alternative pathway of the cleavage o f  P-amyloid 
precursor protein (P-APP) that yields amyloid-type fiagments in AD. The activated 
astrocytes express structural proteins such as GFAP, adhesion molecules, and S-IOOp (S- 
lOOP is one o f two 10 kDa isoforms o f  the S-100 protein). Activated astrocytes also 
respond to IL-1 by producing IL-6, IL-8, TNF-a, and S-lOOp. In AD, activated 
astrocytes form a "halo" around neuritic plaques.
Inflamatory mechanisms are evident in the pathogenesis of Alzheimer’s Disease.
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Acute-phase proteins, such as al-antichymotrypsin and C-reactive protein, and activated 
astroglia are found in patients with AD. IL- 6  is detectable in a significant proportion of 
plaques in patients with dementia (Hull, 1996). IL- 6  is also suspected in the regulation o f 
the production o f APP. A single gene on chromosome 21, containing 19 exons o f  which 
three are alternatively spliced producing eight different isoforms, encodes the APP 
protein. Patel and colleagues (1997) showed that deposition o f amyloid P-protein and an 
increase in APP751 to APPggs ratio is evident in AD. The isoform Appzsi mRNA is 
expressed in astrocytes while the isoform APPggg mRNA is mainly expressed in neurons. 
Overexpression of APPg9s does not induce neuropathological changes while 
overexpression o f APP7S1 and similar isoforms leads to progressive impairment in 
leaming and memory. Ringheim and colleagues (1998) found that IL - 6  in the presence 
IL-6 sr induces the P-APP promoter activity within 2 h followed by elevated levels o f P- 
APP. In addition, mRNA transcripts o f human brain tissue and cell cultures 
demonstrated the presence of the alternatively spliced IL- 6  receptor mRNA, suggesting 
the production o f IL-6 sr protein. They conclude that the IL-6 sr may enhance IL- 6  effects 
on target cell populations resulting in increased P-APP expression in AD.
Cognitive impairment is a hallmark condition in AD. Heyser and colleagues (1997) 
examined the cognitive functions o f transgenic mice that chronically expressed IL- 6  from 
astrocytes. The transgenic mice were monitored over a period o f  time (3 ,6 , and 12 
months) regarding their ability to remember correct pathways through a Y-shaped maze 
using footshock as a reinforcement. The avoidance response to footshock fell as the 
transgenic mice aged indicating a potential alteration in brain pathophysiology due to 
chronic expression o f  IL-6 . The aged transgenic mice showed a marked increase in
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iininunostaîning for GFAP indicating an increase in microgliosis that may correspond to 
avoidance leaming.
The cytokine IL-1 is an inflammatory mediator and has been implicated in the 
progression o f  neurodegeneration. Griffin and colleagues (1998) present a role for IL-1 
and S-lOOp as key components in the cellular events leading to AD progression. This 
group describes a cytokine-cycle due to the overexpression o f  IL-1. Autocrine effects 
can lead to IL-I stimulated glial cells, which in turn release IL-1 and EL-6. These 
cytokines can each activate and increase the expression o f  S-IOOP and the synthesis and 
processing o f PAPP. The over expression of cytokines and S-IOOP may result in 
neurotoxic effects. Due to neuronal damage and loss resulting from the IL-I driven 
events, microglia are further activated to increase the release o f IL-1 thus continuing the 
cycle. Aging can result in a progressive increase o f  IL-1 expression as well as S-lOOp.
The monoamine neurotransmitters N £ and serotonin are affected in patients with 
AD. Neurons show evidence o f  degeneration correlating with decreased levels of NE and 
serotonin (McDonald et al., 1991). Bonaccorso and colleagues (1998) examined the 
availability o f  tryptophan in patients with AD. Results showed that in normal patients the 
availability o f plasma tryptophan to the brain decreases with age and with the activation 
o f the immune system (an increase in serum IL-6 was measured). Melatonin, a 
metabolite o f serotonin has been shown to play a role in Parkinson’s Disease (Willis et 
al., 1999). The administration o f  melatonin, and its natural release, may exacerbate 
Parkinson’s Disease raising a possible role for melatonin in movement disorders. 
Oxidative stress is one recognized characteristic o f Parkinson’s Disease. Melatonin is a 
known free radical scavenger with a reported 5-fold greater efficiency in neutralizing free
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radicals than the endogenous antioxidant GSH peroxidase (i.e. peroxide detoxification) 
(Beyer et al., 1998). Thus, melatonin may provide a therapeutic role in reducing firee 
radical tissue damage in disorders such as inflammation and neurodegenerative diseases.
Enzyme-Linked Immunosorbent Assay (ELISA)
Detection o f molecular species can be accomplished by two means; bioassays or 
immunoassays. Bioassays are based on a biological activity while immunoassays are 
based on immunological recognition. The use o f  specific antibodies as reagents have led 
to a growing field o f  immimoassay based protocols (Gee et al., 1994). Because o f  the 
high afSnity o f antibodies for antigens, immunoassays are capable o f measuring 
substances in complex matrices without extraction, purification or concentration. This 
allows for a simplified procedure with the capability to process many samples in a short 
period o f time (Edwards, 1996).
Immunoassays are analytical techniques that depend upon an antigen-antibody 
reaction that is characterized by the Law o f Mass Action:
[Antibody + Antigen (free) <=> Antibody-Antigen (bound) Complex]
An immimoassay that involves the binding o f antigen to antibody followed by a physical 
separation o f the bound antigen from the unbound antigen is a heterogeneous 
immunoassay. A heterogeneous immunoassay requires a separation o f  bound and free 
reagent throughout the assay by washing the solid phase (e.g., wells o f a microtiter plate) 
with a buffer containing a  surfactant (e.g.. Tween 20). Homogeneous immunoassays do 
not require a physical separation technique (e.g., fluorescent polarization immunoassay) 
(Chan, 1987).
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An enzyme-linked immunosorbent assay (ELISA) is a common heterogeneous assay 
format. The enzyme label can be detected by a variety o f  methods, including the 
absorbance of a product measured colormetrically. The chromophore product is formed 
enzymatically from a chromogenic substrate. Often the enzymatic reaction is terminated 
with a stopping solution, such as sulfuric acid or hydrochloric acid. The chromophoric 
absorption spectrum is changed with the stopping solution, and readings are made on a 
microplate reader at an appropriate wavelength (Little, 1996). The enzyme horseradish 
peroxidase (HRP) is a hydrogen-peroxidase oxidoreductase enzyme that transfers 
hydrogen from hydrogen donors by the following reaction (Ngo, 1991):
HRP
HOOH + 2 Hydrogen Donor 2 H2O + 2 Oxidized Donor
The HRP activity is measured indirectly by the rate o f transformation o f the hydrogen 
donor. TMB (3,3’,5,5’-tetramethybenzidine), in the presence o f HRP and hydrogen 
peroxide, forms a one-electron oxidation product that is blue in color (653 nm 
wavelength). When a stopping solution is added, the acid yields the diimine terminal 
oxidation product that is yellow in color (450 nm).
Principle Hypotheses o f This Study 
The development o f the novel lL-6 ELISA is based on previous work by Gee and 
colleagues (1994). This ELISA format has been successful for detection of 
environmental compounds. The immunoassay design is based on the ability to coat the 
wells o f a 96-well plate with an antigen (i.e., compound o f  interest). The use o f a 
primary antibody and an enzyme-labeled secondary antibody allows for the completion
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
17
of the immunoassay design. Upon addition of the substrate, color development occurs 
and is stopped by the addition o f an acid. The endpoint color development is then read at 
a wavelength o f 450 nm. This ELISA procedure is applied to the development o f the 
novel indirect lL-6 ELISA.
lL-6 plays a role in inflammation and neurodegeneration. The elucidation of 
mechanisms involved in the control o f the release o f lL-6 in the brain is an area o f 
interest for developing therapeutic interventions. Catecholamines, especially 
norepinephrine, act synergistically with IL-ip in stimulating the  release o f lL-6 from rat 
C6 glioma cells in vitro (Zumwalt et al., 1999). lL-1 receptor antagonist has been 
reported to inhibit IL-ip signal transduction by binding to the same lL-1 Type 1 receptor 
(Dinarello, 1997). Serotonin, another monoamine, has been reported to increase lL-6 
mRNA in rat hippocampal astrocytes (Pousset et al., 1996). M y research objectives in 
this study are to first develop an lL-6 ELISA and secondly to identify the mechanisms 
surrounding the release o f lL-6 from C6 glioma cells.
I . Development o f an indirect lL-6 ELISA
Ho The development o f an indirect ELISA is not achievable for the 
measurement o f  lL-6 
Ha The development of an indirect ELISA is achievable for the 
measurement o f  lL-6
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
18
2. Effects o f lL - ip  and IL-lra
Ho IL-1P and IL- Ira will not affect IL-6 release from C6 glioma cells 
Ha IL-1P will have an affect on lL-6 release from C6 glioma cells 
This effect will be prevented by the addition o f  IL-lra
3. Effects o f Serotonin
Ho Serotonin will not effect lL-6 release from C6 glioma cells 
Ha Serotonin will affect lL-6 release from C6 glioma cells
Serotonin and IL -lp will work synergistically on lL-6 release
4. Effects o f Melatonin
Ho Melatonin will not effect lL-6 release from C6 glioma cells 
Ha Melatonin will affect lL-6 release from C6 glioma cells
Melatonin and IL -ip will work synergistically on lL-6 release
The development o f  a novel ELISA for the detection o f lL-6 will be compared to the 
existing 7TD1 bioassay currently used in our laboratory. The comparison will include 
standard curves and assay sensitivities. The findings from the above investigations will 
also help in the elucidation o f  signal transduction pathways for the stimulation o f  lL-6 
release from rat C6 glioma cells thus providing further evidence o f  the cytokine- 
neuroendocrine role in inflammation and neurodegeneration.
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MATERIALS AND METHODS
Chemicals and Reagents 
(Bu^cAMP, p-mercaptoethanol, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyI 
tétrazolium bromide), isopropanol (reagent grade), penicillin G, streptomycin sulfate, 
gentamycin sulfate, melatonin, and serotonin were obtained from Sigma Chemical Co. 
(St. Louis, MO). RPMI-1640, fetal calf serum (PCS), frmgizone, horse serum (HS), and 
trypsin were obtained from Gibco (Grand Island, NY). Thymosin fraction 5 (TF5) was 
generously provided by Dr. Allan L. Goldstein, George Washington University School o f 
Medicine, Department o f Biochemistry and Molecular Biology (Washington, D C ) .  
Recombinant rat IL-ip (IL-IP) was obtained from PeproTech Inc. (Rocky Hill, NJ). 
Recombinant murine lL-6 (rmIL-6), recombinant human lL-1 receptor antagonist (IL- 
lra), and recombinant human EL-6 soluble receptor (lL-6sr) were obtained from R & D 
Systems (Minneapolis, MN). Dr. J. Van Snick, Ludwig Institute (Brussels, Belgium), 
generously provided the 7TD1 hybridoma cell line. The C6 glioma cell line was obtained 
from the American Tissue Type Culture Collection (Rockville, MD).
C6 Glioma Cell Culture 
C6 glioma cells were maintained in continuous culture in a humidified atmosphere o f
19
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5% C02-95% air at 37 “C in complete RPMI-1640. Complete RPMI-1640 inlcudes 7.5% 
horse serum (HS), 2.5% fetal calf serum (PCS) and antibiotics (7.5 pg/mL streptomycin, 
15 pg/mL gentamycin, 19 pg/mL penicillin, 0.6 ^ig/mL fungizone). After 2-3 days in 
culture, cells were removed from the tissue culture flasks with 0.25% trypsin in 
phosphate-buffered saline, resuspended in serum-free RPMI-1640, and counted by 
hemacytometer. The cells were then either placed in continuous culture (1.0 x 10  ̂cells 
per 25 cm" flask, Greiner) or were dispersed into 12-well tissue culture plates (800 x 10̂  
cells/well, Palcon) for the measurement o f  lL-6 using the ELISA assay. C6 cells were 
also dispersed into 96-well tissue culture plates (Greiner) at 100 x 10  ̂cells/well with 
complete RPMI-1640 for the measurement o f lL-6 using the 7TD1 bioassay.
Por ELISA experiments, the cells were allowed to adhere for 24 h, rinsed twice with 
serum-free RPMI-1640 medium (sfRPMl), and then incubated for 24 h with vehicle 
(sfRPMl), or 1% complete RPMI-1640, in the absence or presence o f 500 ng/mL TP5 (1 
mL per well). Conditioned media was removed and stored at 4 °C pending analysis for 
lL-6 by ELISA.
For 7TD1 bioassay experiments, the cells were allowed to adhere for 
24 h, rinsed twice with sfRPMl, and then incubated for 24 h with vehicle (sfRPMl) in the 
absence or presence o f IL-ip, monoamines, or other agents (200 pL per well). In some 
experiments, C6 cells were pretreated with IL-lra for 30 min or monoamines for 10 min 
in sfRPMl medium and subsequently exposed to the compounds of interest in the absence 
or presence o f 1L-1(3. Conditioned media was removed and stored at 4 °C pending 
analysis for lL-6 by bioassay.
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ELISA Reagents
Recombinant rat IL-6 and polyclonal rabbit anti-rat lL-6 were obtained from 
Antigenix America (Franklin Square, New York). Goat anti rabbit IgG horseradish 
peroxidase (HRP) enzyme conjugate and 3,3’,5,5’-tetramethybenzidine (TMB) hydrogen 
peroxide enzyme substrate solution were obtained from Chemicon International, Inc. 
(Temecula, CA). Tween 20 was obtained from Sigma Chemical Co. (St. Louis, MO).
ELISA Instrumentation and Equipment 
Nunc-lmmuno MaxiSorp Surface microplates were used for all ELISA procedures 
(Nalge Nunc International, Denmark). ELISA absorbances were read in the end point 
mode (450 nm) with a Dynatech MR5000 plate reader (Dynex Technologies, the new 
Dynatech Laboratories, Chantilly, VA).
Optimization o f ELISA Procedure 
The optimization o f the ELISA procedure for the detection o f IL-6 and the indirect 
ELISA format was accomplished by adapting an immunoassay technique from the U. S. 
Environmental Protection Agency (Gee et al., 1994). Antigen-coated plates were 
achieved by passive absorbance o f  the lL-6 antigen to the Maxisorb plate surface. A 
solution o f coating antigen (CoAg) in carbonate coating buffer (0.1 M NaHCOg, pH 8.2) 
was added to a plate (150 pL/well). The CoAg was prepared with lL-6 and the dilutions 
typically ranged from 6 ng/well to 0.094 ng/well. Each dilution was added to one o f the 
twelve columns o f the plate (one dilution/column). The plate was covered with acetate 
sealer tape, and stored overnight at 4 °C.
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On the following day, the plate was washed three times with 200 pL o f phosphate 
buffered saline with 0.1% Tween-20 (PBST). The rabbit anti-IL-6 antibody was serially 
diluted 1:500 to 1:6400 in PBST and 150 pL was added to one o f  the eight rows o f  the 
washed plate (one dilution/row). The plate was sealed and incubated at ambient 
temperature for 3 h and then washed as before. Goat anti-rabbit IgG HRP conjugated 
antibody (1:5000) was added (150 piL/well), and the plate was covered for a 2 h 
incubation (ambient temperature). After washing as before, 100 pL o f the TMB enzyme 
substrate solution was added to the wells for seven to ten minutes o f color development.
A stopping solution o f  0.25 M HCl was added (100 ^L/well) resulting in a color change 
that was read within five min at 450 nm on the plate reader.
ELlSA-lndirect Format 
Day One: The coating antigen was prepared with 3 ng/well o f  lL-6 as determined by 
the reagent optimization assays. The plate was covered with sealer tape, and stored 
overnight at 4 °C. On the same day, lL-6 standards were diluted in PBST and 300 jiL o f 
each standard was added to 12 x 75 mm polystyrene plastic tubes typically ranging from 
100 ng/mL to 0.25 ng/mL (including a zero standard). The glial cell condition medium 
was also added to plastic tubes (300 pL/tube). Rabbit anti-lL-6 antibody was diluted 
1:750 and 300 \iL o f  this solution was added to the tubes containing IL-6 standards and 
samples resulting in a final antibody dilution o f 1:1500 (as determined by reagent 
optimization assays). The tubes containing these incubation solutions were sealed, and 
the antibody was allowed to react with the IL-6 overnight at ambient temperature.
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Day Two: The IL-6 antigen-coated plates were washed three times with PBST (200 
pL/well). The pre-incubated solutions from day one were added to the antigen-coated 
plates in triplicate (150 fxL/well) and allowed to incubate, covered, for 3 h at 21 “C. After 
washing the plates again with PBST, 150 pL o f a solution in PBST o f goat anti-rabbit 
IgG labeled with HRP enzyme conjugate (1:5000 dilution) was added to each well.
Plates were covered, incubated for 2 h a t 21 °C, and washed for a final time with PBST. 
100 pL o f the enzyme substrate TMB solution was added to each well for seven to ten 
minutes allowing for color development. A stopping solution o f 0.25 M  HCl was added 
( 100 pL) to the wells resulting in a color change that was read at 450 nm within 5 min 
using the plate reader. A general schematic o f  the ELISA procedure is outlined in 
Figure 5.
ELISA Data Handling 
Construction o f a calibration curve is based on a four-parameter logistic equation 
that results in a monotonie, smooth continuous curve. The four-parameter logistic 
equation is defined by
y = ((A -  D)/ (1 + (x/C)®l + D 
where y is the absorbance, x is the concentration o f antigen, A and D are the upper and 
lower asymptotes respectively, B is the slope and C is the central point on the linear 
region o f  the curve termed as the ICso (Figure 6). At least 6 standard curve points are 
used with this model (two more calibrator points than the number o f parameters 
estimated). The ICso values are calculated based on the four-parameter curve logistic fit
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using SOFTmax PRO Version 2.1.1 software (Molecular Devices Inc., Palo Alto, CA). 
Data are presented as the mean ± standard error o f the mean (SEM) consisting o f 3 to 4 
observations per experimental group.
7TD1 Bioassay for IL-6 
The accumulation o f  IL-6 in the C6 glioma cell conditioned media was quantified 
using the IL-6-dependent 7TD1 hybridoma bioassay as previously described (MacLeod et 
al., 1993), with minor modifications. This particular IL-6 sensitive hybridoma has not 
responded to a variety o f  cytokines or hormones including IL-1, interferon-a and ~P, 
tumor necrosis factor (TNF)-<x, prolactin (PRL), or growth hormone (GH) (Spangelo, 
1990). The 7TD1 cells were maintained in continuous culture in a humidified 
atmosphere o f 5% COz-95% air at 37 °C in 10 mL RPMI-1640 supplemented with 5%
FCI (Fetal Clone I; Hyclone, Logan, UT), 50 pM P-mercaptoethanol, 5 pg/mL rmIL-6, 
and antibiotics. Approximately 400 x 10̂  7TD1 cells were distributed in a 25 cm^ flask 
(Greiner) for continuous culture. Conditioned medium (20 pL) was cultured in 96-welI 
tissue culture plates in duplicate for 72 h in the presence o f4,000 7TD1 cells/well in 200 
pL o f RPMI-1640 supplemented with 5% FCI, 50 pM P-mercaptoethanol, and 
antibiotics. The extent o f  7TDI proliferation was determined using the tétrazolium salt 
MTT, which is cleaved in active mitochondria to form a dark blue formazan product.
After a 72 h incubation period, 20 pL of 5 mg/mL MTT was added to each well for 4 h. 
Following removal o f 150 pL medium firom each well, the dark blue crystals were 
dissolved by the addition o f 150 pL o f 0.04 M HCl/isopropanol. After an overnight 
incubation in the dark, optical densities were obtained in a microelisa instrument using a
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test wavelength o f 570 nm and a reference wavelength o f630 nm (Dynatech MR5000) or 
the Spectra Max Plus plate reader (Molecular Devices Inc., Palo Alto, CA). An empty 
96-well plate was used to zero the microelisa machine. A standard curve o f  rmIL-6 
(0.125-16.0 pg/well) was generated in each assay. Data are presented as the mean ± SEM 
consisting o f 3 to 4 observations per experimental group.
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RESULTS
Optimization of ELISA 
A two dimensional titration (i.e., checkerboard titration) is designed to test two 
reagents simultaneously. The rat IL-6 antigen and the rabbit anti-rat IL-6 antibody were 
not specifically designed to work together in an ELISA format. A checkerboard titration 
will determine the titer o f  the reagent and the dilution required to give a reasonable signal 
for the antigen and anti-antigen antibody. Data analysis o f the checkerboard is achieved 
by plotting the absorbance against the concentration o f the coating antigen for each 
antibody dilution. A family o f  curves is obtained (Figures 7 and 8) such that the 
absorbance increases linearly for any one curve until reaching saturation. The coating 
antigen (CoAg) concentration is determined based on the concentration at which the 
absorbance no longer increases. In Figure 8, the CoAg concentration o f 3 ng is enough to 
trap all antibodies added to the well. The antibody dilution o f 1:1500 for the above CoAg 
concentration gives a reasonable absorbance between 0.5 and 1.5.
Alternatively, the checkerboard data can be analyzed by plotting the absorbance 
against the antibody concentrations for each concentration o f CoAg (Figures 9 and 10). 
The family o f curves shows that the absorbance declines as the antibody concentration 
decreases. A steep slope between two antibody dilutions is optimal. Therefore a  small
26
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change in bound antibody would result in a significant change in absorbance. In Figure 
10, the steepest slopes are found in the 1:1000 and 1:2000 antibody range. The 3 ng/well 
IL-6 CoAg has a fairly steep slope in the optimal antibody range. Therefore, from 
Figures 8 and 10, a CoAg concentration of 3 ng/well and an antibody dilution o f 1:1500 
were used for ELISA reagent optimization.
ELISA Standard Curve 
The generation o f  a reproducible standard curve is imperative to developing a 
consistent ELISA method. Plotting the absorbance against the logio o f IL-6 
concentrations generates the standard curve. The IL-6 standards provide a complete 
definition o f the curve that is sigmoidal in shape (2 to 3 points defining the upper and 
lower asymptote and at least 4 points defining the linear region). Figure 11 shows the 
four-parameter logistic calibration curve with an ICso o f  3.1 ng/mL IL-6, a concentration 
corresponding to 50% binding. Absorbance values that fall on the linear portion o f the 
calibration curve (between 1 and 10 ng/mL) are ideal for calculating IL-6 concentrations 
in unknown samples. Absorbance values that fall on the upper or lower asymptotes are 
considered out o f  the calibration curve range o f detection. The limit o f detection for this 
standard curve is 0.25 ng/mL. The limit of detection was determined by identifying the 
lowest concentration o f antigen which can be distinguished from zero and then 
multiplying the standard deviation by three (Howes, 1996).
The standard curve was generated using PBST as the matrix for dilutions o f IL-6 
antigen and o f the rabbit anti-rat IL-6 antibody. C6 cells were subjected to 50-500 pg/mL 
TF5, a known stimulator o f  IL-6 release from C6 cells (Tijerina et al., 1998). IL-6 in
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these samples was not detectable on the ELISA IL-6 standard curve because values were 
in the upper asymptote range o f the standard curve (data not shown). The C6 conditioned 
medium consists o f  serum-free RPMI (sfRPMl) and other components released during 
the 24 h incubation period which might affect antibody-antigen binding capabilities. To 
test this possible matrix interference, IL-6 standard curves were generated comparing 
PBST, sfRPMl and 1% complete RPMI (i.e., complete RPMI is diluted 1:10) matrices 
(Figure 12). The 1% complete RPMI standard curve has a decreased detection range 
compared to the sfRPMl and PBST curves with IC50 values o f  4.89, 5.41 and 5.54 
respectively. The shifting o f the standard curve to the left allows for increased sensitivity 
(i.e., lower ICso) but results in decreased resolution o f the points on the curve (i.e., curve 
becomes less steep). In Figure 12, the standard curves for the different matrices do not 
result in a noticeable left shift leading to increased sensitivity. IL-6 presumably released 
from C6 cells treated with TF5 (500 pg/mL) was not detectable in any o f the above 
standard curves. Therefore, sfRPMl or 1% complete RPMI does not interfere with the 
ELISA format. Thus, the indirect ELISA format is not sensitive enough to detect IL-6 
present in the conditioned medium samples.
7TD1 Bioassay Standard Curve 
Representative bioassay standard curves are shown in Figures 13 and 14. The dose 
response curve obtained from the relationship between nnIL-6 concentrations and optical 
density approximates a line-of-best-fit equation. In Figure 13, the line-of-best fit is a 
linear regression equation where amounts o f rmIL-6 greater than 8.0 pg/well do not 
provide further linear increases in optical density values; thus, samples need to be diluted
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properly to generate values in the linear portion o f the standard curve. A correlation 
coefficient o f  >0.99 is obtained, and the linear regression equation is easily solved for x- 
axis values. The limit o f detection as determined by three times the standard deviation o f 
a concentration that is not zero (Howes, 1996) for IL-6 in this assay is 5 pg/mL.
In some cases the linear regression equation is not the best fit for the standard 
points given. A logarithmic line-of-best fit equation generates a curve that better 
approximates the standard points in Figure 14. The logarithmic equation allows for 
values o f  IL-6 to be calculated only on the linear portion o f  the curve. Therefore, 
appropriate dilutions o f  the samples are necessary for values to fall on the dynamic range 
o f the logarithmic curve. The correlation coefficient o f  >0.96 is obtained and the 
logarithmic equation is easily solved for x-axis values. In this assay the limit o f 
detection, as defined by Howes (1996), for IL-6 is 2 pg/mL. Depending on the standard 
points, the line-of-best-fit is discretely determined to allow for optimal IL-6 
concentrations to be resolved. Of the two equations, the linear regression model is used 
more often to define the best-of-line fit for the points generated from the rmIL-6 standard 
curve. Table 2 compares the IL-6 ELISA standard curve to the 7TDI standards curves.
Rat Interleukin-ip Time Course and Dose Response 
Rat IL-1 p increased the release o f IL-6 in a concentration and time-dependent 
maimer (Figure 15). The basal release o f IL-6 firom C6 cells was undetectable under 12 h 
o f incubation. After 12 h o f incubation there is a steady basal increase o f IL-6 resulting 
in a 12.4-fold increase at 48 h in comparison to 12 h. The baseline detection o f IL-6 
results fi’om the amount o f IL-6 release firom the C6 cells cultured in sfRPMl medium at
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each time point. Therefore, the increase in the baseline is a time-dependent event. The 
concentration response showed that 5 -1 0 0  ng/mL IL -ip  generated similar increases in 
IL-6 release at all time points. A concentration o f  50 ng/mL IL -ip  at the 24 h incubation 
period was used for all subsequent experiments (Figure 16). The increase in IL-6 release 
from C6 cells was maximal between 5 and 100 ng/mL IL-ip.
Effects of Rat Interleukin-1 Receptor Antagonist 
IL -lra  binds to both Type I and Type H IL-1 receptors thereby preventing IL -lp 
from binding and transducing a signal. IL -ip (10 and 50 ng/mL) stimulated IL-6 release 
(83.5 db 10 pg/well and 165 ± 24 pg/well, respectively) (Figure 17). hi the presence o f  IL- 
lra (100 ng/mL), IL-6 release was reduced in half (41.5 ± 5 pg/well) in the presence of 
10 ng/mL IL -ip  and by a third (58.1 ±  2.6 pg/well) in the presence o f 50 ng/mL EL-ip.
As controls, the vehicle (sfRPMl) and IL-lra (100 ng/mL) resulted in only basal release 
of IL-6 (21.7 ± 2.2 and 25.6 ±  3.0 pg/well, respectively). Therefore, IL-ip stimulation o f 
the IL-6 release from C6 glioma cells is a receptor mediated event.
Effects o f Serotonin, Melatonin and IL -ip  on IL-6 Release 
Our laboratory recently showed that IL-lp and norepinephrine have a synergistic 
effect on the release o f  IL-6 from C6 glioma cells in vitro (Zumwalt et al., 1999). We 
decided to investigate serotonin, another monoamine, for possible synergism with IL-ip 
in releasing IL-6 from C6 cells in vitro. As shown in Figure 18, serotonin (0.5 to
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100 pM) did not affect the basal release o f  IL-6. IL-ip (50 ng/mL) stimulated IL-6 
release to 144 ±  3.3 pg/well. When IL -ip  was combined with varying amounts of 
serotonin no further induction o f  IL-6 occurred.
To further test if serotonin had any synergism with IL-ip for IL-6 release, 
concentrations o f serotonin were reduced to the nM range (Figure 19). The 
concentrations were reduced due to the findings by Pousset and colleagues (1996) who 
demonstrated that maximal IL-6 mRNA was stimulated by serotonin the nM range. 
Serotonin (1 to 100 nM) was incubated by itself or with IL-ip (10 and 50 ng/mL). 
Isoproterenol (IPT) served as a positive control for P-adrenergic receptor synergistic 
enhancement o f IL-6 release. IPT, a P-adrenergic receptor agonist, activates adenylyl 
cyclase to increase cAMP concentrations. Figure 19 shows that indeed IPT (10 pM) in 
the presence o f IL-ip (10 and 50 ng/mL) resulted in a 3-fold induction o f EL-6 release 
from C6 cells. For example, IL-ip (50 ng/mL) increased IL-6 release to 115 ± 10 
pg/well and, while in the presence of IPT, IL-ip synergistically increased IL-6 release 
345 ± 24 pg/well. Serotonin only resulted in the basal release o f  IL-6 in comparison to 
vehicle (srRPMI, 21 ± 3 pg/well IL-6). In the presence o f IL-1 P, serotonin had no 
synergistic effects.
Melatonin, a product o f serotonin breakdown (Figure 4), was also examined for 
potential synergism with EL-ip on IL-6 release from C6 cells. Melatonin (I to 100 nM) 
had no effect on the basal release o f IL-6 (Figure 20). IL-ip (10 and 50 ng/mL) and 
melatonin showed no synergistic ability in releasing IL-6 in comparison to the positive 
control (IPT).
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Effects o f Serum Containing RPMI-1640 
Varying amounts o f diluted complete RPMI and IL-ip were investigated for their 
potential to increase EL-6 release. IL-ip (0.5 to 100 ng/mL) was incubated with sffUPMI, 
0.1%, 1% and complete RPMI (i.e., 0.1% and 1% are dilutions o f  the complete RPMI) 
(Figure 21). Increasing amounts of serum resulted in the increased release of IL-6. 
Exposure to IL-1 P (10 ng/mL) resulted in 74, 176, 223, and 235 pg/well IL-6 in sfRPMl, 
0.1%, 1.0%, and complete RPMI, respectively. This increased induction o f IL-6 when 
combining IL-ip and 0.1% complete RPMI was further investigated. The presence o f 
serum in the experiment may allow for enhanced binding for serotonin. Serotonin (0.5 to 
100 pM) was incubated with IL-ip (50 ng/mL) in 0.1% complete RPMI (Figure 22). IL- 
ip  (50 ng/mL) stimulated the release of IL-6 in 0.1% complete RPMI (178 ±  18 pg/well). 
In addition, serotonin had no synergistic effect when incubated in the presence of IL-1 p. 
Therefore, the use o f 0.1% complete RPMI did not enhance serotonin binding in 
increasing IL-6 release by itself or in the presence o f  IL-1 p.
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DISCUSSION 
Indirect IL-6 ELISA
The development o f  an indirect competitive IL-6 ELISA resulted in an assay with a 
detection range from 1 to 10 ng/mL and an IC50 o f  3.1 ng/mL IL-6 (Figure 11). ELISAs 
in general are multicomponent assays that require careful selection o f reagents, buffers, 
and test parameters to ensure a precise and sensitive assay. The antibody affinity for 
antigen is an important characteristic for assay sensitivity. If  the antibody has too high of 
an affinity for the coating antigen than for the antigen o f interest, an equilibrium shift 
may occur thereby reducing assay sensitivify. The anti-rat IL-6 antibody that incubates 
with EL-6 overnight may also have an equal affinity for the coating antigen (i.e., IL-6 
covalently bound to wells). Different vendors offer paired antibody-antigen sets that 
have been optimized to work together in an immunoassay format. An example o f  these 
paired antibody-antigen sets is ELISA kits. IL-6 ELISA kits for murine IL-6 (Wang et 
al., 1999) and human IL-6 (Loret De Mola et al., 1996) have the ability to detect 15 
pg/mL and 2 pg/mL, respectively. The anti-rat IL-6 antibody and the IL-6 antigen were 
purchased from the same vendor, but they were not offered as a paired set. In using the 
rat IL-6 protein as the coating antigen and in the standard curve, the anti-rat IL-6 
antibody was recognizing the same antigen (i.e., IL-6 coated to the surface o f  the plate 
and IL-6 in the standards). Therefore, reducing the range o f detection from nanograms to
33
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picograms may not be successful due to the high affinity binding o f the antibody to the 
IL-6 antigen.
The antigen coating to the surface o f  wells can be influenced by the solid phase itself 
(e.g., polystyrene, polyvinyl chloride), buffer conditions (i.e., pH, %Tween), and by time 
and temperature (Voiler et al., 1986). IL-6 is a 26 kDa protein that is passively absorbed 
through non-covalent interactions onto the polystyrene plastic wells. A carbonate coating 
buffer with an alkaline pH is recommended for most protein absorbtions. Coating buffers 
with pH o f  8.6 and 9.6 were tested on coating IL-6 to the plates resulting in no difference 
in standard curves (data not shown). A neutral pH is optimal for the phosphate buffered 
saline with Tween-20. A phosphate buffered saline with 0.1% Tween-20 (pH 7.4) was 
used in the IL-6 ELISA. The Tween-20 helps to reduce non-specific binding o f  reagents. 
Non-specific binding (NSB) is the measure o f the HRP-labeled antibody that is not bound 
to anti-rat IL-6 antibody (i.e., the HRP-labeled antibody binds to non-coated portions of 
the plastic well). The addition of Tween-20 during the incubation and washing steps of 
the ELISA aids in the reduction o f NSB. Another method to prevent NSB is to block the 
coated plate. We examined this possibility using bovine serum albumin (BSA). After 
coating the IL-6 to the surface o f  the plate (incubation at 4'*C overnight) the plate was 
washed and then blocked with a 1% BSA (mixed in PBST) for a 1 h incubation period.
The blocking o f  the wells prior to addition o f  the standards did not result in increased 
sensitivity o f the developed ELISA (data not shown).
In troubleshooting the parameters o f the developed assay, guidelines given by Gee 
and colleagues (1994) were followed: hi cases o f  low color development the problem is 
most likely due to decreased enzyme activity, incubation temperature, and possible
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matrix effects. For testing the enzyme activity, increased concentrations (2-5 times) of 
the HRP-labeled antibody were added to the substrate solution (1:5000 dilution) and 
incubated for 2 h. In this instance, the color development was similar to that obtained in 
the assay. Therefore, both the enzyme-labeled antibody and substrate solution were not 
the cause for decreased color (data not shown). Incubation temperatures were kept 
consistent (4°C for the overnight coating step and ambient temperature for the rest of the 
ELISA steps) and were not suspected for possible loss in color development. Matrix 
effects (Figure 12) showed that the use o f  PBST, sfRPMl, and 1% complete RPMI did 
not greatly affect assay conditions. The sfRPMl curve was parallel to the PBST with 
similar ICso values (5.41 and 5.54 ng/mL IL-6). The 1% complete RPMI standard curve 
showed a decreased range o f detection by one-half order o f magnitude. Unknown 
samples would need to fall in the linear portion of either the PBST or sfRPMl standard 
curves for accurate measurement of IL-6. The IL-6 ELISA was not sensitive enough to 
detect any released IL-6 in the condition medium in which the C6 cells were subjected to 
500 Pg/mL TF5. In previous experiments using the 7TD1 bioassay, TF5 (100 pg/mL) 
was shown to increase the release of IL-6 from C6 cells (Tijerina et al., 1998). In 
comparing the bioassay to the ELISA, the bioassay can detect picogram amounts of IL-6 
bioactivity while the developed ELISA is unable to detect IL-6 from conditioned medium 
immunologically (Table 2). The 7TD1 bioassay is a  more sensitive assay for detecting 
EL-6 (pg/well). This assay was used for the remainder o f  the experiments.
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Effects o f IL-1 p and IL-lra on IL-6 Release 
IL-1 P has been shown to stimulate the release o f IL-6 in the human astrocytoma 
cell line U373 (Lieb et al., 1996) and in the rat C6 glioma cell line (Zumwalt et al., 1999). 
Indeed, rat IL-ip stimulated IL-6 release from rat C6 cells in vitro (Figure 16). The 
release o f IL-6 can be detected over a period o f time (Figure 15) o f which a considerable 
amount was released during the 24 to 48 h incubation. IL-ip binds to the IL-1 Type I 
receptor allowing for signal transduction. The exact cascade o f intracellular events has 
yet to be elucidated. Some second messengers that may be involved in signal 
transduction include the G-proteins, cAMP-dependent serine/theronine kinases (PKA), 
protein kinase C (PKC), and lipid metabolism or mediators (Bankers-FuUbright et al., 
1996). Type I receptor mRNA is expressed in astrocytes (Tomozawa et al., 1995) 
confirming that IL-ip stimulation o f IL-6 release is receptor mediated. IL-lra blocks 
signal transducing events by binding to the IL-1 Type I receptor thereby preventing IL-ip 
from binding (Figure 17). Further experiments will include different concentrations of 
IL-lra to find the optimum concentration for blocking IL-6 release in the presence o f  IL- 
ip . The presence o f IL-lra may serve as a defense mechanism to m inim ize the pro- 
inflammatory response of IL-1 p and IL-6. Bresnihan and colleagues (1998) reported the 
therapeutic affects o f using IL-lra (150 mg/day) for treating iheumatoid arthritis. IL-lra 
has also been suggested for blocking IL-1 effects in patients with glomerulonephritis 
(Nikolic-Paterson et al., 1996).
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Effects o f  Serotonin and Melatonin on IL-6 Release 
IL-1 p has been shown to act synergistically with TNF-a in stimulating IL-6 release 
from astrocytes (Maimone et al., 1993; Gayle et al., 1998). Norepinephrine and IL-P also 
work synergistically in releasing IL-6 from astrocytes (Maimone et al., 1993; Zumwalt et 
al. 1999). The monoamines DA, NE, and E were shown to act synergistically, NE having 
the greatest effect, with IL -lp by stimulating IL-6 release from rat C6 cells (Zumwalt et 
al., 1999). Serotonin, another monoamine, did not show synergism with IL -ip  on 
stimulating IL-6 release from rat C6 cells (Figure 18). Serotonin (10^ to 10"'^) can 
increase IL-6 mRNA expression in rat astrocytes (Pousset et al., 1996). The pM 
concentration o f serotonin (Figure 17) was reduced to concentrations in the nM range as 
described by Pousset and investigators (1996) (Figure 19) Wiich again had no synergistic 
effect in the presence o f  IL-1 P in releasing IL-6. NE binds to the P-adrenergic receptor 
and stimulates the production o f  cAMP. IPT, a p-adrenergic agonist, was used as a 
positive marker by synergistically acting with IL -ip  on stimulating the release o f  IL-6 
(Figures 19 and 20). Melatonin, a product o f  serotonin metabolism, did not have a 
synergistic effect with IL -ip  on releasing IL-6 from C6 cells (Figure 20). IL-ip 
incubated in 0.1% complete RPMI stimulated IL-6 release 3-fold compared to sfRPMl 
(Figure 21 ). Serotonin and IL -lp were incubated in 0.1% complete RPMI on the C6 cells 
(Figure 22) which again had no synergistic effect on releasing IL-6 from C6 cells. IL -ip 
stimulated the release o f IL-6 from astrocytes but not in a synergistic maimer with the 
monoamine serotonin, or its metabolite, melatonin.
Serotonin can bind to a variety o f receptors (Table 1) o f which 5 -HT2 receptor is 
predominantly found on astrocytes (Hansson et al., 1987). The S-HT2 receptor is linked
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to the breakdown o f  inositol phospholipid resulting in inositol monophosphate and 
diacylglycerol. In the above studies, serotonin may be binding to S-HTz receptors, which 
is not synergistically linked to the IL-1 p signal transduction pathway. Further 
investigations will be designed to identify if  the presence o f  serotonin has inhibitory 
effects on IL-6 release. Serotonin will be incubated in the presence o f  IL-1 p and IPT. 
Present results showed that IPT and IL-lp have a synergistic effect on IL-6 release, in the 
presence o f serotonin, this synergistic response may be reduced.
In the study by Pousset and colleagues (1996) serotonin increased IL-6 mRNA 
within I hour o f  incubation but the IL-6 protein was not concomitantly measured. The 
induction o f IL-6 mRNA and protein release would be an area for further investigation. 
One way to determine i f  intracellular IL-6 is present in the cell would be to harvest the 
cells and then perform cell lysis. Intracellular IL-6 concentration could be measured 
using the 7TD1 bioassay.
Role o f  IL-6 and IL-6 Receptors in Neurodegeneration 
IL-6sr is another area for further investigation. IL-6sr binds IL-6 and then signals 
through the gp 130 membrane bound receptor. Glial cells express IL-6 receptor mRNA 
that can be alternatively spliced to form soluble IL-6 receptor (Van Wagoner et al.,
1999). The gpI30 receptor unit can be found in different regions o f the brain since other 
hormones can associate with this particular unit. The increased amounts of IL-6sr allows 
for IL-6 to bind to gpI30 units in different parts o f the brain other than were the classical 
IL-6 membrane bound receptor would be found. Thus, the IL-6sr may enhance the 
overall function o f  IL-6 to otherwise non-responsive cell types and to regions of the brain
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distant from the original site o f IL-6 production (Ringheim et al., 1998). Harrison and 
colleagues (1996) demonstrated that monoclonal antibodies for gpI30 could inhibit the 
production o f acute phase reactants. IL-6 induces a systemic acute-phase response 
resulting in fever, and increased fibrinogen, C-reactive protein and platelet count. The 
use of anti-gpI30 antibodies may present another role for developing treatments for 
inflammatory conditions.
Circulating levels o f  IL-6sr are under investigation for their potential role in AD. 
Angelis and colleagues (1998) measured serum levels o f IL-6sr in AD patients and found 
a reduction suggesting a dysregulation of IL-6sr and IL-6 in AD. A decrease in IL-6sr 
was also found in the cerebrospinal fluid of AD patients (Hampel et al., 1998). The ratio 
o f EL-6:EL-6 receptor;IL-6sr is 1:1000:60000 with IL-6 having low affinity to IL-6 
receptor and a higher affinity to IL-6sr and the gpl30 unit. Marz and colleagues (1997) 
found cerebrospinal fluid levels o f IL-6, IL-6sr and gpl30 unchanged in patients with 
AD, but these levels do not reflect potential alterations o f the IL-6 receptor system in 
specific brain regions o f  AD. The link between IL-6, IL-6sr and the membrane bound 
pgI30 receptor unit are still under investigation for their effects in AD.
W ith the evidence o f the potential role IL-6 plays in the inflam m ato ry  and 
neurodegenerative processes, the elucidation o f its activation and release are pertinent for 
developing therapeutic interventions. IL-6 levels are increased in Alzheimer's Disease 
(Hull et al., 1996; Mrak, et al., 1995), Parkinson's disease, AlD's related dementia. Down 
syndrome dementia (Kalman et al., 1997), autoimmune disorders (Graeve et al., 1993) 
and ovarian hyperstimulation syndrome (Loret De Mola et al., 1996). The release o f  IL-6 
from activated glial cells may be responsible for the cleaveage o f  the P-amyloid precursor
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protein resulting in the amyloid fragments found in AD. In particular, the am yloid 
precursor protein isoform 751 may play an important role in the progressive impairm en t 
in learning and memory (Mrak et al., 1995; Patel et al., 1997). Changes in 
catecholamines and catecholaminergic neurotransmission are known in AD. The 
synergistic mechanism o f ME and IL-1(3 on releasing IL-6 from glial cells is one way 
catecholamines can modulate immunological responses in the brain. Alterations in 
serotonin metabolism may also play a role in AD. Bonaccorso and colleagues (1998) 
reported a correlation between levels o f tryptophan, precursor to serotonin, and an 
increase in serum IL-6 from elderly patients with AD. From the above experiments, 
serotonin directly increasing the release o f lL-6 was not foimd in the C6 glioma cells 
(Figures 18 and 19).
Conclusion
The development o f a sensitive, reliable lL-6 ELISA was attempted in this study.
The LOD for lL-6 was 0.25 ng/mL with a detection range o f 1-10 ng/mL. Therefore, 1 
reject the null hypothesis and accept the alternative hypothesis for the development o f  the 
EL-6 ELISA. Due to the lack in sensitivity for IL-6 measurement in comparison to the 
7TD1 bioassay, the ELISA was not chosen as the detection method. The 7TD1 bioassay 
LOD for EL-6 was 2-5 pg/mL and therefore was implemented as the detection method for 
measuring IL-6 in the experiments described in this study.
There is strong evidence for cytokines in the promulgation of inflam m ato ry  and 
neurodegenerative diseases. EL-ip and IL-6 are found to be principle cytokines in 
exacerbating acute phase immune response. IL-ip, by itself or synergistically with
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catecholamines, activates glial cells to release EL-6. EL-Ira inhibits the release of IL-6 
providing a potential therapeutic model. From these results, I reject the null hypothesis 
and accept the alternative hypothesis stating the effects o f IL-ip increased the release o f 
IL-6 from C6 glioma cells which was inhibited in the presence o f IL-lra. Serotonin and 
melatonin do not directly stimulate IL-6 release alone or in the presence o f IL-ip. 
Therefore, I accept the null hypotheses that serotonin and melatonin do not have an effect 
on the release o f lL-6 by themselves or in the presence o f EL-ip. Currently under 
investigation are the potential inhibitory effects serotonin may have on EPT and IL -ip 
synergistic release o f IL-6 from C6 glioma cells.
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Table 1. Mammalian 5-HT Receptor Subtypes and Their Signal Transduction Pathway 
(adapted from Cooper et al., 1996).
G-Protein Coupled 
Receptors
Receptor
Subtype
G-Protein Signal Transduction Pathway
5-HTi Family 5-HT lA, IB. ID. IE Gi Inhibition o f Adenylyl Cyclase
5 -HT2 Family 5-HT2A.2B.2C Gq Phosphoinositide Hydrolysis
Others 5-HT 4 Gs Activation o f Adenylyl Cyclase
5-HT 5A.5B ? Unknown coupling mechanism
5-HT 6 Gs Activation o f Adenylyl Cyclase
5-HT 7 Gs Activation o f Adenylyl Cyclase
Ligand-Gated Ion 
Channel
5-HT 3 None Ligand-Gated Ion Channel 
(mostly on neurons)
G, Inhibitory G-Protein Associated Receptor 
Gs Stimulatory G-Protein Associated Receptor 
Gq Phosphoinositide G-Protein Associated Receptor
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Table 2. Comparison o f IL-6 ELISA and 7TDI Standard Curves.
IL-6 ELISA 7TDI Bioassay
Line-of-Best Fit 4-Parameter Curve Linear Regression Logarithmic
Equation o f the Line y = (a-d)/(l+(x/c)''b)+d y = mx + b y = mLn(x) + b 
Detection Limit 0.25 ng/mL 5 pg/mL 2 pg/mL
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Hypothalamus
Median Eminence
Hypophysial Arteries 
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Pituitary
Hypophysial Portal Vessels
(Secondary Plexus)
Figure I. Vascularization o f the pituitary gland bv hvpophvsial arteries and portal 
vessels in relation to the hypothalamus.
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Figure 2. Biosynthesis of Catecholamines.
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idenytyl
Plasma Membrane
cAMP
Figure 3. G-protein Signal Transduction. A  neurotransminer (A or B) binds to the select 
receptor (Rs or Ri) resulting in an appropriate cellular response. When A binds to a 
receptor with stimulatory efifects (Rs), the Rs associates with a Gs subtype protein. The 
resulting cellular response is activation o f adenylyl cyclase leading to the production of 
cAMP. When B binds to a receptor with inhibitory effects (Ri). the Ri associates with the 
Gi subtype protein thereby inhibiting adenylyl cyclase and the production o f  cAMP.
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Figure 4. Synthesis and Metabolism o f Serotonin.
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Day 1:
Coat wells with DL-6 
( 100 fjL/well)
Rinse Plate 
3 X with PBST
Incubate IL-6 or Sample with 
Rabbit anti-rat IL-6 Antibody
Bound and Free Antibody
Day 2:
Add incubated samples (150 ^iL/well) to the rinsed plate and incubate 
3 h at ambient temperature 
(Free Antibody Binds IL-6 Coated to Plate)
Rinse Plate 3 x with PBST
Add HRP Labeled Goat anti-rabbit Antibody (150 ^L/well) 
and incubate 2 h at ambient temperature 
(Secondary Antibody binds Primary Antibody)
Rinse Plate 3 x with PBST
Add TMB substrate solution ( 100 pL/well) 
Color Develops within 10-20 min
Blue Color Deyelops
Add 0.25 M HCl Stopping Solution (100 pL/well) 
Read Plate within 5 min at 450 nm on plate reader 
(Blue Color Turns Yellow)
Figure 5. General Schematic for the IL-6 ELISA.
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C
D..
Log Concentration
Figure 6. Four Parameter Logistic Curve Model. The equation o f the line consists of the 
following four parameters: A equals the upper asymptote, B equals the slope o f  the linear 
portion o f the curve and C is the IC50 and D is the lower asymptote. The curve is 
sigmoidal in shape and graphed on a logarithmic x-axis scale.
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Figure 7. Checkerboard titration of IL-6 antigen plotted against the absnrhanrt» 
for each anti-rat IL-6 antibody dilution. Varying amounts of IL-6 (0 to 6 
ng/well) were incubated with diluted antibody (1:500 to 1:64,000) for 2 h 
(following the ELISA optimization procedure). Each data point represents one 
observation.
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Figure 8. Checkerboard Titration o f IL-6 antigen plotted against the absorbance 
for each anti-rat IL-6 antibody dilution. Varying amounts of IL-6 (0 to 6 ng/well) 
were incubated with diluted antibody (1:1000 to 1:2000) for 2 h (following the 
ELISA optimization procedure). Data are presented as the mean ± SEM of each 
antigen concentration consisting of triplicate observations per concentration.
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Figure 9. Checkerboard titration o f anti-rat IL-6 antibody duiutions against 
absorbance for each IL-6 coating antigen concentration. Varying amounts of 
IL-6 (0 to 6 ng/well) were incubated with dulted antibody (1:500 to 1:64,000) 
for 2 h (following the ELISA optimization procedure). Each data point 
represents one observation.
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Figure 10. Checkerboard titration o f anti-rat IL-6 antibody dilutions against 
absorbance for each IL-6 coating antigen concentration. Varying amounts of IL-6 
(0 to 6 ng/well) were incubated with diluted antibody (1:1000 to 1:2000) for 2 h 
(following the ELISA optimization procedure). Data are presented as the mean ± 
SEM of each antibody dilution consisting of triplicate observations per dilution.
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Figure 11. IL-6 ELISA Standard Curve. Four-parameter logistic calibration curve with a 
R." value o f 0.99 and an value o f  3 1 ng/mL. Equation parameters for the upper and 
lower asymptopes are 0.77 and 0.05 respectively, and 1.09 for the slope o f the linear 
portion o f the curve. The data are expressed as the mean ̂  SEM for points consisting 
o f three observations.
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Figure 12. Matrix Effects. Standard curves were generated using PBST, sfRPMI, and 
1.0% serum containing RPMI as the matrix. IL-6 (0.5 to 100 ng/mL) standard dilutions 
were made into each matrix and incubated with anti-rat IL-6 antibody (following IL-6 
ELISA protocol). Four-parameter curve fitting resulted in IC50 values o f 5.54, 5.41,4.89 
respectiv ely. The data are presented as the mean ± SEM for each group consisting o f 
three observations per group.
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Figure 13. 7TD1 cell hinassay standard curve with a linear regression line 
of-best fit equation. Cells were cultured for 72 h in the absence or 
presence o f  increasing amounts o f rmIL-6. Optical density values were 
obtained with M TT, as described in text. The data presented are a mean 
±  SEM  for points consisting o f four observations.
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Figure 14. 7TD1 cell bioassav standard curve with a loparithmic Ihie-og- 
best fit equation. Cells were cultured for 72 h in the absence or presence 
o f increasing amounts of imIL-6. Optical density values were obtained 
with MTT, as described in text. The data presented the mean ±  SEM for 
each point consisting o f four observations.
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Figure 15. Interleukin 1 p srimulates IL-6 release from C6 glinma cells Cultured C6 
cells ( 100 X 10  ̂cellsAveU) were exposed to either vehicle (sfRPMI) or different 
concentrations o f IL -ip  from 8 • 48 h. IL^ip stimulated IL-6 release at 24 h, 36 h, 
and 48 h. The standard error bars are not shown,but for the 8 and 12 h time groiqis 
the %SEM was less than 20% and for the 24, 36, and 48 time groups the %SEM 
was less than 10%.
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Figure 16. Interleukin-IB stimulates IL-6 release from C6 glioma cells. 
Cultured C6 cells (100 x 10  ̂cells/well) were exposed to either vehicle 
(sfRPMI) or difiFerent concentrations o f IL-ip for 24 h. The data are 
presented as the mean ±  SEM for concentration groups consisting o f 
four observations per group.
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Figure 17. Effects o f IL-lra and IL-lB on IL-6 release from C6 glioma cells. 
C6 cells (100 X 10  ̂cells/well) were exposed to either vehicle (sfRPMI), IL-lra 
(100 ng/mL), IL-ip (10 or 50 ng/mL), and IL-lra + IL-I(3 for 24 h. The data 
are expressed as the mean ±  SEM of each treatment group consisting o f four 
observations per group.
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Figure 18. Effects of Serotonin and IL-lB on the Release of IL-6 from C6 glioma 
cells. C6 cells (100 x 10̂  cells/well) were incubated with vehicle (sfRPMI), IL -l3 
(50 ng/mL), serotonin (0.5 to 100 jiM), or IL-l 3 + serotonin for 24 b. The data are 
expressed as the mean ± SEM of each treatment group consisting of four 
observations per group.
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Figure 19. Effects of Serotonin and IL-1B on IL-6 Release from C6 glioma cells.
C6 cells (100 X 10̂  cells/well) were incubated in the presence of vehicle (sfRPMI), 
isoproterenol (IPT) (10 jaM), IL-ip (10 and 50 ng/mL), IPT 4- IL -l3, serotonin (I to 
100 nM), or serotonin 4- IL-l3 for 24 h. The data are presented as the mean ± SEM 
of each treament group consisting of 4 observations per group.
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Figure 20. Effects o f Melatonin and IL-IB on IL-6 Release from C6 glioma cells. 
C6 cells (100 X 10  ̂cells/well) were incubated in the presence of vehicle (sfRPMI), 
isoproterenol (IPT) (10 uM), IL-ip (10 and 50 ng/mL), IPT + IL-ip, melatonin 
(1 to 100 nM), or melatonin -r- IL-ip for 24 h. The data are presented as the mean 
= SEM of each treament group consisting o f four observations per group.
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Figure 21. Eflfects o f  serum cnntaininp RPMI and H ^ ip  on IL-6 release. C6 cells 
( 100 X 10  ̂cells/well) were exposed to differenct concentrations o f  IL -ip  (0.2 to 
100 ng/mL) in serum-free RPMI (sfRPMI), 0.1%, 1%, or conçlete RPMI. The 
data are presented as the mean ±  SEM o f groups consisting o f four observations
per group.
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Figure 22. FfTect.s o f 0 1% complete RPML Serntnnin and IL-16 on tt^6  
R elease. C6 cells (100 x 10  ̂cells/well) were incubated in the presence o f vehicle 
(0.1% complete RPMI), IL-lp (50 ng/mL), serotonin (0.5 to 100 pM), or IL^ip + 
serotonin for 24 h. The data are presented as the mean ±  SEM o f each group 
consisting o f four observations per group.
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